P1B is found in 2 entries.

P1B as free ligands, exist in 2 entries. Examples include 2XKW 4A79

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

Name (5R)-5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione
Identifiers (5R)-5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
Formula C19 H20 N2 O3 S
Molecular Weight 356.439  g/mol
Type non-polymer
Isomeric SMILES CCc1ccc(CCOc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc1
InChI InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)/t17-/m1/s1

Chemical Details

Formal Charge 0
Atom Count 45
Chiral Atom Count 1
Chiral Atoms C5
Bond Count 47
Aromatic Bond Count 12
Leaving Atoms n/a

Drug Info: DrugBank

DrugBank ID DB01132   (Different stereochemistry)
Name Pioglitazone
  • approved
  • investigational
Description Pioglitazone is used for the treatment of diabetes mellitus type 2. Pioglitazone selectively stimulates nuclear receptor peroxisone proliferator-activated receptor gamma (PPAR-gamma). It modulates the transcription of the insulin-sensitive genes involved in the control of glucose and lipid metabolism in the lipidic, muscular tissues and in the liver.
  • (+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
  • Pioglitazona
  • Pioglitazone
  • Pioglitazonum
  • (+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
  • Pioglitazona
  • Pioglitazone
  • Pioglitazonum
Brand Names
  • Accel Pioglitazone
  • Ach-pioglitazone
  • Act Pioglitazone
  • Actoplus Met
  • Actoplus Met XR
Affected Organism Humans and other mammals
Indication Treatment of Type II diabetes mellitus
Pharmacology Pioglitazone, a member of the drug group known as the thiazolidinediones or "insulin sensitizers", is not chemically or functionally related to the alpha-glucosidase inhibitors, the biguanides, or the sulfonylureas. Pioglitazone targets insulin resistance and, hence, is used alone or in combination with insulin, metformin, or asulfonylurea as an antidiabetic agent.
Mechanism of action Pioglitazone acts as an agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors increases the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, pioglitazone both enhances tissue sensitivity to insulin and reduces hepatic gluconeogenesis. Thus, insulin resistance associated with type 2 diabetes mellitus is improved without an increase in insulin secretion by pancreatic β cells.
Route of administration
  • occlusive dressing technique
  • oral
Categories Hypoglycemic Agents
ATC-Code A10BG03
AHFS-Code 68:20.28
CAS number 111025-46-8

Drug Targets

Name Sequence Search Pharmacological Action Actions
Peroxisome proliferator-activated receptor gamma MGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDL... yes agonist
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682